Under ideal circumstances, the trials should recruit patients with a type of cancer highly dependent on p53 mutations; in other words, the p53 mutation should be a key driver in this cancer type and the cancer cells depend on the p53 mutation to survive and/or grow. The gene discussed is TP53; the disease is cancer.